Attention cash-strapped private biotechs: Whether you're struggling to find a bridge across the valley of death or trapped in a windowless venture portfolio, don't give up hope just yet, because four bills making their way through Congress could revolutionize your options for fundraising. Read More
Shares of Alimera Sciences Inc. and partner pSivida Corp. plunged Friday afternoon in the wake of a second complete response letter for diabetic macular edema drug Iluvien (fluocinolone acetonide intravitreal insert). Read More
Results from a study published this week suggest a way to get the benefits of one class of diabetes drugs - thiazolidinediones, or TZDs, such Actos (pioglitazone, Takeda Pharmaceutical Co. Ltd.) and Avandia (rosiglitazone, GlaxoSmithKline plc) - without their side effects. Read More
After nearly a year of anticipation, NewLink Genetics Corp., of Ames, Iowa, priced its initial public offering of 6.2 million shares at $7 per share, with an underwriters' option of 930,000 additional shares. The offering could raise $49.9 million for the biotech, which specializes in cancer immunotherapeutics. Read More
• KAI Pharmaceuticals Inc., of South San Francisco, reported Phase II results showing that KAI-4169, its long-acting intravenous calcium sensing receptor agonist, was effective in treating secondary hyperparathyroidism in patients with chronic kidney disease, with 33 percent and 49 percent reductions in parathyroid hormone (PTH) from baseline in the 5-mg and 10-mg dose groups, respectively (p < 0.05 vs. placebo for both groups). In the 10-mg group, 76 percent of subjects achieved greater than or equal to 30 percent reduction in PTH, and 67 percent of subjects achieved a PTH level 300 less than or equal to pg/mL at the end of the treatment period. Data were presented at the American Society of Nephrology's Kidney Week meeting in Philadelphia. Read More
In lieu of a much-promised and oft-delayed guidance on social media, biopharma has been told to apply existing guidance on drug promotion to online communication. But in many instances, that's like trying to fit a square peg into a round hole. Read More
DUBLIN, Ireland - Genable Technologies Ltd. raised €5 million (US$6.8) million in a Series B financing round to take forward a mutation-independent gene therapy approach for treating an autosomal-dominant form of retinitis pigmentosa (RP). Read More
• Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen, Denmark, said they entered a long-term agreement to develop and commercialize up to five psychiatric and neuroscience products worldwide. Read More
Researchers from the Korean Ewha Women's University identified a population of dendritic cells - immune system cells that present antigens to other immune system cells - which protect against the development of cardiovascular disease. Read More